CN107847587B - Cd30×cd16抗体与pd-1拮抗剂的联合药物 - Google Patents

Cd30×cd16抗体与pd-1拮抗剂的联合药物 Download PDF

Info

Publication number
CN107847587B
CN107847587B CN201680026411.5A CN201680026411A CN107847587B CN 107847587 B CN107847587 B CN 107847587B CN 201680026411 A CN201680026411 A CN 201680026411A CN 107847587 B CN107847587 B CN 107847587B
Authority
CN
China
Prior art keywords
antibody
combination
cells
cd16a
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680026411.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN107847587A (zh
Inventor
马丁·特里德
乌维·罗伊施
延斯-彼得·马什纳
斯特凡·奈克马斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affimed GmbH
Original Assignee
Affimed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP15166303.6A external-priority patent/EP3091031A1/en
Application filed by Affimed GmbH filed Critical Affimed GmbH
Publication of CN107847587A publication Critical patent/CN107847587A/zh
Application granted granted Critical
Publication of CN107847587B publication Critical patent/CN107847587B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680026411.5A 2015-05-04 2016-05-04 Cd30×cd16抗体与pd-1拮抗剂的联合药物 Active CN107847587B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15166303.6A EP3091031A1 (en) 2015-05-04 2015-05-04 Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor
EP15166303.6 2015-05-04
EP16152650.4 2016-01-25
EP16152650 2016-01-25
PCT/EP2016/060113 WO2016177846A1 (en) 2015-05-04 2016-05-04 Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy

Publications (2)

Publication Number Publication Date
CN107847587A CN107847587A (zh) 2018-03-27
CN107847587B true CN107847587B (zh) 2020-10-09

Family

ID=56026814

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680026411.5A Active CN107847587B (zh) 2015-05-04 2016-05-04 Cd30×cd16抗体与pd-1拮抗剂的联合药物

Country Status (20)

Country Link
US (1) US11167029B2 (cg-RX-API-DMAC10.html)
EP (1) EP3292153B1 (cg-RX-API-DMAC10.html)
JP (1) JP6609784B2 (cg-RX-API-DMAC10.html)
CN (1) CN107847587B (cg-RX-API-DMAC10.html)
AU (1) AU2016257334B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017023579A2 (cg-RX-API-DMAC10.html)
CA (2) CA2983706C (cg-RX-API-DMAC10.html)
CY (1) CY1122283T1 (cg-RX-API-DMAC10.html)
DK (1) DK3292153T3 (cg-RX-API-DMAC10.html)
ES (1) ES2754557T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20191933T1 (cg-RX-API-DMAC10.html)
HU (1) HUE045866T2 (cg-RX-API-DMAC10.html)
LT (1) LT3292153T (cg-RX-API-DMAC10.html)
PL (1) PL3292153T3 (cg-RX-API-DMAC10.html)
PT (1) PT3292153T (cg-RX-API-DMAC10.html)
RS (1) RS59489B1 (cg-RX-API-DMAC10.html)
RU (1) RU2761352C2 (cg-RX-API-DMAC10.html)
SI (1) SI3292153T1 (cg-RX-API-DMAC10.html)
SM (1) SMT201900598T1 (cg-RX-API-DMAC10.html)
WO (1) WO2016177846A1 (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018158349A1 (en) * 2017-02-28 2018-09-07 Affimed Gmbh Tandem diabody for cd16a-directed nk-cell engagement
AU2018226526B2 (en) 2017-02-28 2025-03-13 Affimed Gmbh Combination of an anti-CD16A antibody with a cytokine
CN109706164A (zh) * 2017-10-26 2019-05-03 深圳新诺微环生物科技有限公司 微环dna表达连接人和猴cd20与效应细胞抗原的桥接分子及其应用
CN109706163A (zh) * 2017-10-26 2019-05-03 深圳新诺微环生物科技有限公司 微环dna表达连接人与动物靶细胞与效应细胞的桥接分子及其应用
WO2019175368A1 (en) * 2018-03-14 2019-09-19 Affimed Gmbh Bispecific egfr/cd16 antigen-binding protein
EP3774914A2 (en) * 2018-04-13 2021-02-17 Affimed GmbH Nk cell engaging antibody fusion constructs
PL3843757T3 (pl) * 2018-08-27 2024-08-05 Affimed Gmbh Kriokonserwowane komórki nk wstępnie obciążone konstruktem przeciwciała
CN109402168A (zh) * 2018-10-30 2019-03-01 深圳新诺微环生物科技有限公司 微环dna表达连接her2阳性细胞与效应细胞的桥接分子及其应用
GB2603044B (en) * 2019-06-11 2024-08-21 Myeloid Therapeutics Inc Macrophage specific engager compositions and methods of use thereof
CA3160927A1 (en) * 2019-12-27 2021-07-01 Affimed Gmbh Method for the production of bispecific fcyriii x cd30 antibody construct
US20240101677A1 (en) * 2021-01-27 2024-03-28 Innovent Biologics (Suzhou) Co., Ltd. Single-domain antibody against cd16a and use thereof
JP2024524378A (ja) 2021-06-29 2024-07-05 山▲東▼先声生物制▲薬▼有限公司 Ｃｄ１６抗体及びその応用
AR127298A1 (es) 2021-10-08 2024-01-10 Genmab As Anticuerpos que se unen a cd30 y cd3
WO2023080895A1 (en) * 2021-11-04 2023-05-11 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and multispecific engagers
EP4426350A4 (en) * 2021-11-04 2025-09-24 Artiva Biotherapeutics Inc Treatment of cancer with nk cells and multispecific engagers
CN116059348A (zh) * 2022-09-16 2023-05-05 四川大学华西医院 基于nkg2d的细胞接合器分子在清除衰老细胞中的应用
WO2024114676A1 (zh) 2022-11-29 2024-06-06 江苏恒瑞医药股份有限公司 Cldn18.2/4-1bb结合蛋白及其医药用途
TW202506178A (zh) 2023-04-05 2025-02-16 丹麥商珍美寶股份有限公司 包含與ｃｄ３０和ｃｄ３結合之抗體之醫藥組成物
CN117442721B (zh) * 2023-12-20 2024-03-15 苏州艾凯利元生物科技有限公司 一种包括nk细胞和nk细胞接合器分子的组合物
CN118791616A (zh) * 2024-09-14 2024-10-18 苏州为度生物技术有限公司天津分公司 一种抗人cd16工程抗体及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
DK1907000T4 (da) * 2005-06-08 2020-03-30 The President And Fellows Of Harvard College Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1).
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
EP3183269A2 (en) * 2014-08-22 2017-06-28 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody

Also Published As

Publication number Publication date
WO2016177846A1 (en) 2016-11-10
CY1122283T1 (el) 2020-11-25
CA3219372A1 (en) 2016-11-10
RU2017137251A (ru) 2019-06-04
SI3292153T1 (sl) 2020-01-31
AU2016257334B2 (en) 2021-08-12
BR112017023579A2 (pt) 2018-07-24
PL3292153T3 (pl) 2020-02-28
SMT201900598T1 (it) 2020-01-14
JP2018514576A (ja) 2018-06-07
HK1253022A1 (zh) 2019-06-06
PT3292153T (pt) 2019-11-05
AU2016257334A1 (en) 2017-11-09
RU2761352C2 (ru) 2021-12-07
CA2983706A1 (en) 2016-11-10
JP6609784B2 (ja) 2019-11-27
RS59489B1 (sr) 2019-12-31
HUE045866T2 (hu) 2020-01-28
EP3292153B1 (en) 2019-07-31
RU2017137251A3 (cg-RX-API-DMAC10.html) 2019-10-10
EP3292153A1 (en) 2018-03-14
ES2754557T3 (es) 2020-04-20
US20180085456A1 (en) 2018-03-29
CN107847587A (zh) 2018-03-27
US11167029B2 (en) 2021-11-09
CA2983706C (en) 2024-01-02
HRP20191933T1 (hr) 2020-01-10
LT3292153T (lt) 2019-11-11
DK3292153T3 (da) 2019-10-21

Similar Documents

Publication Publication Date Title
US11167029B2 (en) Combination of a CD30XCD16 antibody with a PD-1 antagonist for therapy
US12065492B2 (en) Anti-B7-H6 antibody, fusion proteins, and methods of using the same
US20250163152A1 (en) Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
AU2014351308B2 (en) Compositions comprising anti-CEACAM1 and anti-PD antibodies for cancer therapy
US20170015758A1 (en) Compositions And Methods For Modulating And Redirecting Immune Responses
US20260116971A1 (en) Antibodies specific to human nectin-2
JP2019514846A (ja) 免疫チェックポイントモジュレーターとのｔ細胞リダイレクティング多機能抗体の組み合わせとその使用
CN111108124B (zh) 新型抗体以及treg消耗性抗体和免疫刺激性抗体的组合使用
CN110248668A (zh) 用于消耗调节性b10细胞的抗体和方法以及与免疫检查点抑制剂的联用
EP3066128A1 (en) Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma
CN111542544A (zh) 用于治疗癌症的免疫刺激性激动性抗体
US20250115667A1 (en) Dosing of a bispecific antibody that binds pd1 and ctla4
CN117813320A (zh) 嵌合蛋白和免疫治疗方法
CN113728009A (zh) 双特异性CD123 x CD3双抗体在血液系统恶性肿瘤治疗中的给药方案
EP3091031A1 (en) Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor
JP2023554422A (ja) がんの治療のための多重特異性抗体
TWI790193B (zh) 調控免疫反應之方法及抗體
HK1253022B (en) Combination of a cd30xcd16 antibody with a pd-1 antagonist

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1253022

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant